Related Experiment Video
Updated: Dec 7, 2025
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Targeting TAM to Tame Pancreatic Cancer
Mitchell S von Itzstein1,2, Michael C Burke1,2, Rolf A Brekken3
1Division of Hematology/Oncology, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-8852, USA.
Abstract:
Pancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mechanistic investigations and therapeutic combinations in the preclinical setting suggest that TAM inhibition with chemotherapy, targeted therapy, and immunotherapy should be evaluated clinically.
Insights
Pancreatic cancer is a growing threat. Targeting TAM receptor tyrosine kinases (Tyro3, Axl, MerTK) shows promise for new pancreatic cancer treatments, potentially combined with existing therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic cancer is a leading cause of cancer death, with limited effective treatments.
- Current therapies face challenges due to resistance and disease progression.
- The TAM receptor tyrosine kinase subfamily (Tyro3, Axl, MerTK) is linked to pancreatic cancer's aggressive traits.
Purpose of the Study:
- To highlight the role of TAM receptors in pancreatic cancer.
- To explore TAM inhibitors as a novel therapeutic strategy.
- To investigate the potential of combining TAM inhibition with other treatments.
Main Methods:
- Review of preclinical data on TAM receptor tyrosine kinases in pancreatic cancer.
- Analysis of the implications of TAM signaling in metastasis, chemoresistance, and immune suppression.
- Examination of proposed therapeutic combinations involving TAM inhibitors.
Main Results:
- TAM receptors are implicated in the metastatic, chemoresistant, and immunosuppressive nature of pancreatic cancer.
- TAM inhibitors demonstrate potential for targeting multiple facets of pancreatic cancer biology.
- Preclinical evidence supports the evaluation of TAM inhibition in combination therapies.
Conclusions:
- TAM inhibitors represent a promising investigational approach for pancreatic cancer.
- Combining TAM inhibition with chemotherapy, targeted therapy, or immunotherapy warrants clinical investigation.
- Novel therapeutic strategies targeting TAM signaling are urgently needed for pancreatic cancer.
